Healthcare Industry News: Covalon Technologies
News Release - April 26, 2006
FDA Approval Received On Covalon's New Collagran'TM' And Collagran Ag'TM' Advanced Wound Dressings With Matrix Metalloprotease 'MMP' Inhibiting ActivityMISSISSAUGA, ONTARIO--(Healthcare Sales & Marketing Network)--Apr 26, 2006 -- Covalon Technologies Ltd. ("Covalon") (TSX VENTURE:COV.V ) announces that the FDA has approved Covalon's proprietary CollagranTM and Collagran Ag(TM) new collagen-based wound dressings for use in the USA.
The FDA approval of Covalon's proprietary collagen-based Collagran(TM) and its antimicrobial silver ion-releasing Collagran Ag(TM) wound dressings represents a significant milestone for the company. The new dressings, when applied to decubitus and other wounds, create a beneficial wound healing environment. Collagran(TM) and Collagran Ag(TM) inhibit the activity of matrix metalloproteases (MMPs) that are known to be detrimental to optimal wound healing. The dressings absorb wound exudates to form a soft and conformable collagen-based, hydrophilic pad that is gas permeable. Furthermore, Collagran Ag(TM) provides antimicrobial silver ions that provide a biocidal microbial barrier in the dressing. The amount of soluble silver provided in Collagran Ag(TM) is known by in vitro testing to kill Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE) and fungicidal-resistant Candida albicans, as well as many other pathogenic microbes. Collagan(TM) and Collagran Ag(TM) advanced dressings are indicated for use on pressure ulcers, diabetic ulcers, venous ulcers, first and second degree burns, donor and graft sites, abrasions and lacerations, dehisced surgical wounds and traumatic wounds healing by secondary intention.
In the International Review of Patient Care, Wound care management, page 47, Frost and Sullivan's Tanya Pullen points out that global revenues from the advanced dressings market is expected to reach US$4b. Value-added-dressings are expected to show expanding market uptake with the overall US wound management market approaching US$ 1.7b in 2009 (http://www.irpcare.com/articles/wound_care_mang/PAC003_046.pdf).
Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Source: Covalon Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.